GlassScriptPhysician profile
Kevin E Suttmoeller
NPI 1144201914
$197,921.52
in general payments reported to CMS, 2019-2025
63 companies · $32K in 2025
The $32K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $18K · 2021: $28K · 2022: $28K · 2023: $21K · 2024: $18K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Food and Beverage: $9,060 · Travel and Lodging: $5,962 · Education: $88.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,282.64 |
| Food and Beverage | $9,060.38 |
| Travel and Lodging | $5,961.51 |
| Education | $88.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $186,356.23 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,813.22 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,199.42 | 2020-2025 | Farxiga, Airsupra, Fasenra |
| Lilly USA, LLC | $1,141.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Regeneron Healthcare Solutions, INC. | $572.06 | 2023-2024 | Dupixent, Evkeeza |
| Glaxosmithkline, LLC. | $537.91 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $511.34 | 2020-2025 | Jardiance, Ofev, Synjardy |
| Amgen INC. | $477.79 | 2020-2025 | Otezla, Repatha, Evenity |
| Janssen Pharmaceuticals, INC | $468.69 | 2020-2023 | Spravato, Xarelto |
| Pfizer INC. | $378.51 | 2021-2025 | |
| Genzyme Corporation | $307.35 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $305.57 | 2020-2025 | Belsomra, Dificid, Zerbaxa |
| Nevro Corp. | $293.51 | 2020-2024 | Senza |
| United Therapeutics Corporation | $218.41 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $202.09 | 2021-2024 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $200.47 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.71 | 2021-2025 | Xifaxan |
| Currax Pharmaceuticals LLC | $182.30 | 2020-2023 | Nexletol |
| Sumitomo Pharma America, INC. | $180.08 | 2023-2024 | Gemtesa |
| Eisai INC. | $178.29 | 2019-2021 | |
| Insulet Corporation | $156.62 | 2023 | Omnipod |
| Astellas Pharma US INC | $132.53 | 2023-2025 | Veozah |
| Axsome Therapeutics, INC. | $126.58 | 2023-2025 | Auvelity, Sunosi |
| Grifols USA, LLC | $102.00 | 2023-2024 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $100.92 | 2023-2024 | Wakix |
| E.R. Squibb & Sons, L.L.C. | $93.48 | 2021-2025 | Eliquis |
| Vivus LLC | $81.05 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $78.73 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $76.66 | 2022-2024 | Quviviq |
| Amarin Pharma, INC. | $75.25 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.47 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $68.38 | 2022 | |
| Baxter Healthcare | $59.94 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Teva Pharmaceuticals USA, INC. | $58.29 | 2022-2024 | Austedo Xr |
| Boston Scientific Corporation | $57.83 | 2021-2023 | Watchman Access System |
| Mylan Specialty L.P. | $57.18 | 2023-2024 | Yupelri |
| Ardelyx, INC. | $50.87 | 2024 | Ibsrela |
| Sanofi Pasteur INC. | $49.11 | 2022-2023 | |
| Biogen, INC. | $47.50 | 2021-2022 | |
| Radius Health, INC. | $46.79 | 2023 | Tymlos |
| Inogen, INC. | $46.69 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Shield Therapeutics INC | $44.06 | 2023-2025 | Accrufer |
| Neurocrine Biosciences, INC. | $42.65 | 2022 | |
| Ibsa Pharma INC. | $41.91 | 2022-2023 | Tirosint, Licart |
| Daiichi Sankyo INC. | $39.89 | 2019-2024 | Injectafer |
| Cequr Corporation | $39.13 | 2023 | Cequr Simplicity |
| Alnylam Pharmaceuticals INC. | $35.34 | 2023 | Amvuttra |
| Otsuka America Pharmaceutical, INC. | $32.96 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $30.30 | 2021-2024 | |
| Nalpropion Pharmaceuticals LLC | $27.87 | 2019 | |
| Xeris Pharmaceuticals, INC. | $25.76 | 2022 | |
| Amneal Pharmaceuticals LLC | $24.88 | 2025 | Unithroid |
| Esperion Therapeutics, INC. | $24.67 | 2020 | |
| Tactile Systems Technology INC | $21.84 | 2024 | Entre Plus, Flexitouch Plus |
| Sunovion Pharmaceuticals INC. | $19.82 | 2022 | |
| Genentech USA, INC. | $18.78 | 2024 | Xolair |
| Exact Sciences Corporation | $16.89 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $15.38 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $15.03 | 2024 | Opsumit, Uptravi |
| Organogenesis INC. | $14.89 | 2021 | |
| Endo Pharmaceuticals INC. | $14.24 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.80 | 2022 | |
| Endogastric Solutions, INC | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Suttmoeller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.